基于抗体的多发性骨髓瘤中B细胞成熟抗原（BCMA）靶向治疗 - Suppr | 超能文献

Antibody-based targeting of BCMA in multiple myeloma.

作者信息

Morgan Gareth J, Williams Louis

机构信息

NYU Langone Health, New York, NY 10016, USA.

NYU Langone Health, New York, NY 10016, USA.

出版信息

Lancet Oncol. 2020 Feb;21(2):186-187. doi: 10.1016/S1470-2045(19)30819-8.

DOI:10.1016/S1470-2045(19)30819-8

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Antibody-based targeting of BCMA in multiple myeloma.基于抗体的多发性骨髓瘤中B细胞成熟抗原（BCMA）靶向治疗

Lancet Oncol. 2020 Feb;21(2):186-187. doi: 10.1016/S1470-2045(19)30819-8.

2

Phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma.抗BCMA抗体药物偶联物AMG 224用于复发/难治性多发性骨髓瘤患者的1期研究。

Leukemia. 2021 Jan;35(1):255-258. doi: 10.1038/s41375-020-0834-9. Epub 2020 Apr 21.

3

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.B 细胞成熟抗原（BCMA）在多发性骨髓瘤中的作用：靶向治疗的原理和当前的治疗方法。

Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.

4

Multiple Myeloma: The CAR T-cell Therapy Landscape.多发性骨髓瘤：CAR-T 细胞治疗全景。

Cancer Discov. 2020 Feb;10(2):OF6. doi: 10.1158/2159-8290.CD-ND2019-015. Epub 2020 Jan 8.

5

Antibody treatment in multiple myeloma.多发性骨髓瘤的抗体治疗。

Clin Adv Hematol Oncol. 2021 Mar;19(3):166-174.

6

Focus on monoclonal antibodies targeting B-cell maturation antigen (BCMA) in multiple myeloma: update 2021.聚焦于多发性骨髓瘤中靶向B细胞成熟抗原（BCMA）的单克隆抗体：2021年更新

Br J Haematol. 2021 May;193(4):705-722. doi: 10.1111/bjh.17235. Epub 2020 Nov 20.

7

BCMA-targeting approaches for treatment of multiple myeloma.BCMA 靶向治疗多发性骨髓瘤。

Panminerva Med. 2021 Mar;63(1):28-36. doi: 10.23736/S0031-0808.20.04121-X. Epub 2020 Sep 21.

8

Effectiveness and infectious complications of BCMA T-cell engagers in treating multiple myeloma: Real-world evidence from Sweden.BCMA T细胞衔接器治疗多发性骨髓瘤的有效性和感染并发症：来自瑞典的真实世界证据。

Cancer Med. 2024 Apr;13(8):e7048. doi: 10.1002/cam4.7048.

9

BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma.靶向BCMA的双特异性抗体，其同时刺激NKG2D增强对多发性骨髓瘤的疗效。

J Immunother. 2020 Jul/Aug;43(6):175-188. doi: 10.1097/CJI.0000000000000320.

10

Targeting BCMA in Multiple Myeloma.多发性骨髓瘤中的 BCMA 靶向治疗。

Curr Hematol Malig Rep. 2021 Oct;16(5):367-383. doi: 10.1007/s11899-021-00639-z. Epub 2021 Aug 25.

引用本文的文献

1

Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.双特异性抗体治疗复发或难治性多发性骨髓瘤的疗效和安全性：前瞻性临床试验的系统评价和荟萃分析。

Front Immunol. 2024 Feb 28;15:1348955. doi: 10.3389/fimmu.2024.1348955. eCollection 2024.

2

Caveolin-1 in Kidney Chronic Antibody-Mediated Rejection: An Integrated Immunohistochemical and Transcriptomic Analysis Based on the Banff Human Organ Transplant (B-HOT) Gene Panel.肾慢性抗体介导性排斥反应中的小窝蛋白-1：基于班夫人类器官移植（B-HOT）基因面板的综合免疫组织化学和转录组学分析

Biomedicines. 2021 Sep 26;9(10):1318. doi: 10.3390/biomedicines9101318.